Ocugen Announced That The Data And Safety Monitoring Board For OCU410 ArMaDa Clinical Trial Recently Convened And Approved The Continuation Of The Second Phase Of The Phase 1/2 Study

Ocugen宣布，OCU410 ArMaDa临床试验的数据和安全监测委员会最近召开会议，批准继续进行第一/第二阶段研究的第二阶段。

Benzinga · 2024/12/19 03:43

OCU410 (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

OCU410 (AAV5-hRORA) 是一种新型修饰基因治疗候选药物，正在开发用于由于干性年龄相关性黄斑变性 (dAMD) 导致的地理性萎缩 (GA)。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Ocugen Announced That The Data And Safety Monitoring Board For OCU410 ArMaDa Clinical Trial Recently Convened And Approved The Continuation Of The Second Phase Of The Phase 1/2 Study

Ocugen Announced That The Data And Safety Monitoring Board For OCU410 ArMaDa Clinical Trial Recently Convened And Approved The Continuation Of The Second Phase Of The Phase 1/2 Study

风险及免责提示

声明